Drug Trial Radar · NCT00483652
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Last checked: Nov 20, 2026Latest source record: Feb 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
May 2007
Primary completion
Feb 2008
Study completion May 2008
Sponsor
- Lead sponsor
- Acorda TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 7, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to show that individuals treated with Fampridine-SR tablets are significantly more likely to have consistent improvements in their walking than those treated with placebo tablets.
Conditions
- Multiple Sclerosis
Interventions
Fampridine-SRDrug
Tablets, 10 mg, twice daily, 9 weeks
PlaceboDrug
placebo (sugar pill)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responders Based Upon the Timed 25-Foot Walk [T25FW]Time frame: Days -21, -14, -7, 0, 14, 28, 42, 56, 63, 77
Locations
40 sites in 2 countries. Site status is shown where the registry gives one.
Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center
Phoenix, Arizona
HOPE Research Institute
Phoenix, Arizona
Neurological Associates
Fayetteville, Arkansas
Alta Bates Summit Medical Center - Research and Education Institute
Berkeley, California
USC, Keck School of Medicine Health Care Consultation Center
Los Angeles, California
UC Davis
Sacramento, California
Yale University MS Center
New Haven, Connecticut
Shepherd Center
Atlanta, Georgia
Consultants in Neurology, Ltd.
Northbrook, Illinois
Indiana University MS Center
Indianapolis, Indiana
Associates in Neurology, PSC
Lexington, Kentucky
Maryland Center for MS
Baltimore, Maryland
Lahey Clinic
Lexington, Massachusetts
The Schapiro Center for MS
Golden Valley, Minnesota
Washington University School of Medicine
St Louis, Missouri
Advanced Neurology Specialists
Great Falls, Montana
UMDNJ
Newark, New Jersey
Gimbel MS Center at Holy Name Hospital
Teaneck, New Jersey
Jacobs Neurological Institute Buffalo General Hospital
Buffalo, New York
Corinne Goldsmith Dickinson Center for MS
New York, New York
Columbia University Multiple Sclerosis Clinical Care Center
New York, New York
University of Rochester
Rochester, New York
SUNY Stony Brook
Stony Brook, New York
CMC - Neuroscience & Spine Institute, Division of Neurology
Charlotte, North Carolina
Raleigh Neurology Associates
Raleigh, North Carolina
Wake Forest University, Dept of Neurology, M.S. Research
Winston-Salem, North Carolina
The Center for Neurological Services
Bismarck, North Dakota
Cleveland Clinic Foundation
Cleveland, Ohio
Ohio State University MS Center
Columbus, Ohio
Oregon Health & Science University, MS Center of Oregon, UHS-42
Portland, Oregon
Thomas Jefferson University Physicians
Philadelphia, Pennsylvania
Neurological Research Center, Inc.
Bennington, Vermont
Fletcher Allen Health Care
Burlington, Vermont
MS Center at Evergreen
Kirkland, Washington
CAMC Health Education & Research Institute
Charleston, West Virginia
Center for Neurological Disorders of Aurora, St. Luke's Medical Center
Milwaukee, Wisconsin
Foothills Medical Center
Calgary, Alberta, Canada
University of British Columbia, Vancouver Coastal Health Research Institute
Vancouver, British Columbia, Canada
River Valley Health c/o Stan Cassidy Centre for Rehabilitation
Fredericton, New Brunswick, Canada
QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site
Halifax, Nova Scotia, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.